» Articles » PMID: 33105837

Proteomic Investigations of Two Pakistani Snake Venoms Species Unravel the Venom Complexity, Posttranslational Modifications, and Presence of Extracellular Vesicles

Overview
Journal Toxins (Basel)
Publisher MDPI
Specialty Toxicology
Date 2020 Oct 27
PMID 33105837
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Latest advancement of omics technologies allows in-depth characterization of venom compositions. In the present work we present a proteomic study of two snake venoms of the genus i.e., (black cobra) and (brown cobra) of Pakistani origin. The present study has shown that these snake venoms consist of a highly diversified proteome. Furthermore, the data also revealed variation among closely related species. High throughput mass spectrometric analysis of the venom proteome allowed to identify for the venom 34 protein families and for the 24 protein families. The comparative evaluation of the two venoms showed that consists of a more complex venom proteome than venom. Analysis also showed N-terminal acetylation (N-ace) of a few proteins in both venoms. To the best of our knowledge, this is the first study revealing this posttranslational modification in snake venom. N-ace can shed light on the mechanism of regulation of venom proteins inside the venom gland. Furthermore, our data showed the presence of other body proteins, e.g., ankyrin repeats, leucine repeats, zinc finger, cobra serum albumin, transferrin, insulin, deoxyribonuclease-2-alpha, and other regulatory proteins in these venoms. Interestingly, our data identified Ras-GTpase type of proteins, which indicate the presence of extracellular vesicles in the venom. The data can support the production of distinct and specific anti-venoms and also allow a better understanding of the envenomation and mechanism of distribution of toxins. Data are available via ProteomeXchange with identifier PXD018726.

Citing Articles

Venoms and Extracellular Vesicles: A New Frontier in Venom Biology.

Bala A, Oukkache N, Sanchez E, Suntravat M, Galan J Toxins (Basel). 2025; 17(1).

PMID: 39852989 PMC: 11769160. DOI: 10.3390/toxins17010036.


Ethnomedicinal breakthroughs in snake bite therapy: From folklore to forefront.

Hussain S, Kingsley D Toxicol Rep. 2024; 13:101795.

PMID: 39582926 PMC: 11583806. DOI: 10.1016/j.toxrep.2024.101795.


Three finger toxins of elapids: structure, function, clinical applications and its inhibitors.

Hiremath K, Dodakallanavar J, Sampat G, Patil V, Harish D, Chavan R Mol Divers. 2023; 28(5):3409-3426.

PMID: 37749455 DOI: 10.1007/s11030-023-10734-3.


Bridging the extracellular vesicle knowledge gap: insights from non-mammalian vertebrates, invertebrates, and early-diverging metazoans.

Liegertova M, Janouskova O Front Cell Dev Biol. 2023; 11:1264852.

PMID: 37701784 PMC: 10493277. DOI: 10.3389/fcell.2023.1264852.


Multilevel Comparison of Indian Venoms and Their Cross-Reactivity with Indian Polyvalent Antivenoms.

Deka A, Bhatia S, Santra V, Bharti O, Lalremsanga H, Martin G Toxins (Basel). 2023; 15(4).

PMID: 37104196 PMC: 10142961. DOI: 10.3390/toxins15040258.


References
1.
Bernardoni J, Sousa L, Wermelinger L, Lopes A, Prezoto B, Serrano S . Functional variability of snake venom metalloproteinases: adaptive advantages in targeting different prey and implications for human envenomation. PLoS One. 2014; 9(10):e109651. PMC: 4196926. DOI: 10.1371/journal.pone.0109651. View

2.
Marques P, Esteves A, Lancellotti M, Ponce-Soto L, Marangoni S . Novel acidic phospholipase A from causes inflammation with mast cell rich infiltrate. Biochem Biophys Rep. 2017; 1:78-84. PMC: 5668520. DOI: 10.1016/j.bbrep.2015.03.001. View

3.
King G . Venoms as a platform for human drugs: translating toxins into therapeutics. Expert Opin Biol Ther. 2011; 11(11):1469-84. DOI: 10.1517/14712598.2011.621940. View

4.
Kriebel P, Majumdar R, Jenkins L, Senoo H, Wang W, Ammu S . Extracellular vesicles direct migration by synthesizing and releasing chemotactic signals. J Cell Biol. 2018; 217(8):2891-2910. PMC: 6080930. DOI: 10.1083/jcb.201710170. View

5.
Morgan B, Harris C . Complement therapeutics; history and current progress. Mol Immunol. 2003; 40(2-4):159-70. DOI: 10.1016/s0161-5890(03)00111-1. View